Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
- Boehringer v Teva: Italian court clarifies boundaries of Bolar privilege 11-09-2018
- LSIPR 50 2018: Frank Kalkbrenner 28-08-2018
- SPC export waiver: a long road ahead 23-08-2018
- LSIPR 50 2018: Martyn Andrews 21-08-2018
- LSIPR 50 2018: Alisa Harbin 17-08-2018
Latest europe news
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.